Respiratory Morbidity and GAN Questionnaire
Throughout early follow-up, respiratory morbidity (inhaled corticosteroids ≥ 3 consecutive months and/or respiratory-related hospitalizations) was higher in the EP-BPD group than in other groups (Table 1). In addition, respiratory morbidity differed between the “high severity” and “low severity” BPD subgroups (E-table 5). Moreover, the prevalence of lifetime wheezing episodes was higher in the adolescents with BPD than in other adolescents, but differences only reached statistical significance between EP-BPD and MLP groups after adjusting for potential confounders. We found no significant differences between groups either in current asthma prevalence or in the remaining key questions of the GAN questionnaire (Table 3). There was no association between BPD severity and asthma symptom prevalence (E-table 5).